Welcome to our dedicated page for Intercure Ltd. SEC filings (Ticker: INCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InterCure Ltd. filings document foreign private issuer reports for a medical cannabis company operating as Canndoc. Form 6-K disclosures furnish press releases, interim financial statements, management discussion and XBRL data covering revenue, Adjusted EBITDA, cash flow, cash balances, and production, importation and sales from the company's cannabis operations.
The filing record also covers Nasdaq minimum bid compliance for InterCure's ordinary shares, annual general meeting proxy materials, governance matters, material agreements related to cannabis science and pharmaceutical innovation, and risk disclosures tied to service providers, court proceedings, outstanding checks and operating continuity.
InterCure Ltd. (INCR) announced that Nasdaq’s Listing Qualifications Department confirmed the company has regained compliance with the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement. Nasdaq determined that for the 10 consecutive business days from August 24, 2026 through September 4, 2026, InterCure’s ordinary shares closed at $1.00 per share or greater, closing a prior delisting proceeding.
The company had earlier received a notification on February 25, 2026 that its shares were below $1.00 for 30 consecutive business days and a subsequent delisting notice on September 1, 2026 after not regaining compliance within a 180‑day period ending August 24, 2026. InterCure describes itself as a leading and profitable cannabis company outside North America, operating through its wholly owned subsidiary Canndoc in Israel.
Intercure Ltd. (INCR) filed an amended report to correct the purchase price per unit and warrant exercise price in a previously disclosed private placement, so they properly reflect the company’s 1-for-5 reverse share split effective August 24, 2026. The company completed a private placement of 1,579,028 units, each consisting of one ordinary share and one five-year warrant to purchase one ordinary share, at $4.71 per unit. Each warrant is exercisable at $7.07 per share. The offering closed between August 12 and August 25, 2026. Participation by CEO and Chairman Alexander Rabinovich, who beneficially owns approximately 25% of the company’s ordinary shares, remains subject solely to shareholder approval; all other investors’ participation is not subject to such approval. Gross proceeds to the company were $5.3 million excluding Mr. Rabinovich’s portion, which is expected to be approximately $2.1 million. The company intends to use the proceeds for working capital and to rehabilitate the Nir Oz facility of wholly owned subsidiary Canndoc Ltd. The securities were issued in a private placement exempt from U.S. registration under Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S.
Intercure Ltd. (INCR) reported that on August 12, 2026 it entered into a securities purchase agreement with several investors, including CEO and board chairman Alexander Rabinovich, for a private placement of 1,579,028 units, each comprising one ordinary share and one five-year warrant. Units were priced at $2.918, and each warrant is exercisable at $1.59 per share. The offering closed on August 25, 2026, with shareholder approval required solely for Mr. Rabinovich’s participation; he beneficially owns about 26% of outstanding ordinary shares. Gross proceeds to the company were $5 million, excluding Mr. Rabinovich’s expected participation of approximately $2 million. Intercure plans to use the proceeds for working capital and to rehabilitate the Nir Oz facility of its wholly owned subsidiary Canndoc Ltd. The securities were issued in a private, unregistered offering relying on Section 4(a)(2) and/or Regulation S exemptions.
Intercure Ltd. (INCR) reported that its Chief Financial Officer, Cohen Amos, received a grant of 590,000 employee share options on June 9, 2026. These options relate to Ordinary Shares with an exercise price of $1.00 per share, based on a NIS 3.00 price converted at NIS 2.99 = $1.00. The options became fully vested on June 9, 2026 and expire on June 9, 2028. Following this grant, the reported derivative holdings from this award total 590,000 options held directly.
InterCure Ltd. (INCR) reported a final settlement with the Israeli Tax Authorities and Compensation Fund for NIS 230 million (approximately US$77 million) related to indirect damages from the October 7, 2023 attacks and subsequent war. The company had originally claimed over NIS 300 million and had already received NIS 101 million in advance payments under this claim.
InterCure plans to use its strengthened financial position to accelerate rehabilitation of Canndoc’s flagship Nir Oz cultivation and production facility, which was severely damaged and rendered inoperable, with the aim of returning it to full operations as soon as practicable. Restoring Nir Oz is described as central to rebuilding production capacity and supporting InterCure’s international growth strategy, particularly in the growing German medical cannabis market.
Intercure Ltd. (INCR) filed a new notice of an exempt offering of equity securities and options in connection with the first closing of its acquisition of ISHI (Botanico Ltd.), with consideration consisting of Intercure ordinary shares and options to purchase ordinary shares, relying on Rule 506(b) of Regulation D.
The date of first sale is stated as June 15, 2026, with a reported total amount sold of $0 and no finders’ fees. The issuer’s revenue or asset size is marked as “Decline to Disclose,” and no minimum investment or sales compensation arrangements are listed.
InterCure Ltd. reports that an Extraordinary General Meeting of Shareholders held on August 11, 2026 approved the proposal presented to shareholders, with the required majority. The proposal is described in the Notice and Proxy Statement dated July 22, 2026, which had been furnished earlier to the U.S. Securities and Exchange Commission, including an amendment dated July 27, 2026.
InterCure Ltd. outlines voting procedures for its Extraordinary General Meeting of Shareholders scheduled for August 11, 2026 at 4:00 p.m. (Israel time) in Tel Aviv. The company clarifies that it has not engaged Broadridge or similar providers, so shareholders must follow procedures under the Israeli Companies Law.
Shareholders of record as of July 29, 2026 may vote by attending in person or by submitting a proxy card to the company by 11:59 p.m. Eastern Time on August 10, 2026. Holders through banks or brokers can vote in person with a legal proxy, by mailing or emailing a proxy plus legal proxy, or via the Israel Securities Authority’s electronic voting system on the MAGNA platform up to six hours before the meeting. Proxy materials and forms are available on the ISA, TASE and SEC websites and directly from the company.
InterCure Ltd. is convening an Extraordinary General Meeting of shareholders on August 11, 2026 at 4:00 p.m. Israel time to vote on a proposed 5‑to‑1 reverse share split of its Ordinary Shares and a related amendment to its Articles of Association. This Form 6‑K/A corrects the previously stated meeting date from August 12 to August 11 to comply with a 21‑day statutory notice period under Israeli law.
The reverse split is intended to help regain compliance with Nasdaq Listing Rule 5450(a)(2) after the company received a notice on February 25, 2026 that its closing bid price had been below $1.00 per share for 30 consecutive business days, triggering a 180‑day compliance period ending on August 24, 2026. If shareholders do not approve the reverse split, the company states its shares will likely be delisted from the Nasdaq Global Market and could move to over‑the‑counter trading. Shareholders of record at the close of business on July 29, 2026 (with 59,228,556 Ordinary Shares outstanding as of July 21, 2026) are entitled to vote, and the Board unanimously recommends a vote in favor.
InterCure Ltd. has called an extraordinary general meeting for August 12, 2026 to seek shareholder approval of a 5‑to‑1 reverse share split of its Ordinary Shares and related amendments to its Articles of Association, intended to help maintain its Nasdaq Global Market listing.
Nasdaq notified InterCure on February 25, 2026 that its share price had been below $1.00 for 30 consecutive business days, triggering a 180‑day compliance period ending August 24, 2026. As of July 21, 2026, 59,228,556 Ordinary Shares were outstanding, each with one vote; the record date is July 29, 2026. The Board states that failure to approve the reverse split will likely lead to delisting to an over‑the‑counter market with reduced liquidity and more challenging access to capital, and therefore unanimously recommends voting in favor.